FindTrial
Sign In

Multiple-Dose, Dose-Escalation Study to Evaluate

Multiple-Dose, Dose-Escalation Study to Evaluate

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221342
Enrollment
Unknown
Registered
2010-12-27
Start date
2010-12-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : LY2127399 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Have given written informed consent -Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation -Diagnosis of Rheumatoid Arthritis -Active Rheumatoid Arthritis -Current, regular use of Methotrexate, at a stable dose -Body weight between 40 and 105 kg, inclusive

Exclusion criteria

Exclusion criteria: -Use of excluded medications (reviewed by study doctor) -Have medical findings which, in the opinion of the study doctor, put patient at an unacceptable risk for participation in the study -Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation -Evidence of tuberculosis -Have systemic inflammatory condition other than RA

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026